Positron (OTCMKTS:POSC – Get Free Report) and Pulse Biosciences (NASDAQ:PLSE – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability and dividends.
Earnings & Valuation
This table compares Positron and Pulse Biosciences”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Positron | $590,000.00 | 88.91 | -$2.39 million | ($0.12) | -13.92 |
| Pulse Biosciences | $700,000.00 | 1,329.26 | -$53.58 million | ($1.13) | -12.15 |
Analyst Ratings
This is a breakdown of recent ratings and target prices for Positron and Pulse Biosciences, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Positron | 0 | 0 | 0 | 0 | 0.00 |
| Pulse Biosciences | 1 | 0 | 1 | 0 | 2.00 |
Pulse Biosciences has a consensus target price of $22.00, suggesting a potential upside of 60.23%. Given Pulse Biosciences’ stronger consensus rating and higher probable upside, analysts clearly believe Pulse Biosciences is more favorable than Positron.
Volatility & Risk
Positron has a beta of 0.73, meaning that its stock price is 27% less volatile than the S&P 500. Comparatively, Pulse Biosciences has a beta of 1.8, meaning that its stock price is 80% more volatile than the S&P 500.
Profitability
This table compares Positron and Pulse Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Positron | -592.35% | -278.32% | -88.36% |
| Pulse Biosciences | N/A | -67.70% | -58.89% |
Insider and Institutional Ownership
77.0% of Pulse Biosciences shares are held by institutional investors. 17.2% of Positron shares are held by company insiders. Comparatively, 74.6% of Pulse Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Summary
Pulse Biosciences beats Positron on 12 of the 14 factors compared between the two stocks.
About Positron
Positron Corporation, a nuclear medicine healthcare company, specializes in the business of cardiac positron emission tomography (PET) imaging in the United States. It offers attrius PET scanner, clinical and technical services, and financing solutions enables healthcare providers to accurately diagnose cardiac disease, improve patient outcomes, and practice cost effective medicines. Positron Corporation was incorporated in 1983 and is based in Niagara Falls, New York.
About Pulse Biosciences
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
Receive News & Ratings for Positron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Positron and related companies with MarketBeat.com's FREE daily email newsletter.
